Shockwave Medical Inc
F:36M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shockwave Medical Inc
Net Change in Cash
Shockwave Medical Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shockwave Medical Inc
F:36M
|
Net Change in Cash
$347k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Change in Cash
$1.5B
|
CAGR 3-Years
87%
|
CAGR 5-Years
0%
|
CAGR 10-Years
27%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Change in Cash
-$119.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Change in Cash
$359m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Change in Cash
$906m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
24%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Change in Cash
$1.3B
|
CAGR 3-Years
66%
|
CAGR 5-Years
24%
|
CAGR 10-Years
28%
|
|
Shockwave Medical Inc
Glance View
Shockwave Medical Inc. has established itself as a significant player in the healthcare sector thanks to its innovative approach to tackling calcified cardiovascular disease. Founded with the vision of addressing the inefficiencies and limitations of traditional treatment methods, the company has embarked on a path that fuses medical expertise with cutting-edge technology. The core of Shockwave's operation lies in its proprietary intravascular lithotripsy (IVL) technology, which employs sonic pressure waves to safely and effectively fracture problematic calcium deposits in the arteries. This approach not only enhances the safety profile compared to other invasive procedures but also improves the outcomes for patients enduring complex calcified lesions, a common hurdle in cardiovascular treatments. It's through the pioneering use of this technology that Shockwave Medical generates its revenue. The company's product portfolio, which includes devices like the Shockwave M5 and Shockwave C2 catheters, is designed to cater to a wide spectrum of calcified cardiovascular issues. By selling these devices directly to hospitals and healthcare providers across the globe and supporting them with robust clinical data showing improved patient outcomes, Shockwave has cemented its place in the medical device industry. Furthermore, its business model benefits from recurring revenues as healthcare providers continually purchase these specialized devices for ongoing procedures. This consistent demand underscores the company's balanced approach to innovation and profitability in a market primed for technological advancements.
See Also
What is Shockwave Medical Inc's Net Change in Cash?
Net Change in Cash
347k
USD
Based on the financial report for Mar 31, 2024, Shockwave Medical Inc's Net Change in Cash amounts to 347k USD.
What is Shockwave Medical Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-68%
Over the last year, the Net Change in Cash growth was -100%.